Elan Corp. PLC’s and Johnson & Johnson’s multi-faceted partnership, announced on July 2, addresses the strategic needs of both parties—but also creates new uncertainties. [See Deal]
The beleaguered Irish biotech is selling all rights to its Alzheimer’s disease immunotherapy program (AIP), as well as an 18.4%...